NCT03643328View on ClinicalTrials.gov

Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 14, 2017

Primary Completion Date

December 7, 2020

Study Completion Date

December 7, 2020

Conditions
Staphylococcus Aureus
Interventions
BIOLOGICAL

blood samples

Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.

BIOLOGICAL

nasal swabs

Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.

Trial Locations (1)

42055

CHU de Saint-Etienne, Saint-Etienne

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT03643328 - Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients | Biotech Hunter | Biotech Hunter